Insider Trading March 2, 2026

BCB Bancorp Director Marks $39,850 Purchase; Bank Posts Cannabis-Related Write-Down

Director acquisition recorded via IRA as the lender reports a multi-million charge tied to a cannabis-related REO asset and posts 2025 losses

By Ajmal Hussain BCBP
BCB Bancorp Director Marks $39,850 Purchase; Bank Posts Cannabis-Related Write-Down
BCBP

BCB Bancorp director Mark D. Hogan bought 5,000 shares of the company's common stock on February 27, 2026, paying $7.97 per share for a total of $39,850. The transaction was executed indirectly through an IRA, according to a Form 4 filing. Hogan's holdings now include 627,092 shares directly and 103,352 shares indirectly. The stock trades near its 52-week low, and InvestingPro analysis rates BCBP as undervalued on a Fair Value basis. Separately, the bank recorded a $15.1 million pre-tax write-down tied to a cannabis-related real estate owned property, contributing to quarterly and full-year losses in 2025, while Piper Sandler adjusted its price target to $9.00 and kept a Neutral rating.

Key Points

  • Director Mark D. Hogan purchased 5,000 shares at $7.97 on February 27, 2026, for $39,850; acquisition reported as indirect via an IRA in a Form 4 filing.
  • Following the transaction, Hogan directly owns 627,092 shares and indirectly owns 103,352 shares of BCB Bancorp.
  • BCB Bancorp recorded a $15.1 million pre-tax write-down on a cannabis-related real estate owned property and reported a net loss of $12.5 million for the quarter, contributing to a full-year 2025 loss of $14.5 million.

Insider purchase details

Mark D. Hogan, a director at BCB Bancorp Inc (NASDAQ:BCBP), acquired 5,000 shares of common stock on February 27, 2026. The shares were purchased at $7.97 apiece, for a total transaction value of $39,850. A Form 4 filing with the Securities and Exchange Commission indicates the shares were bought indirectly through an individual retirement account.

The filing shows that after the purchase Hogan directly holds 627,092 shares and indirectly owns an additional 103,352 shares of BCB Bancorp.

Market context and valuation note

BCB Bancorp's shares are trading at $7.91, placing the stock close to its 52-week low of $7.31. InvestingPro analysis included with the report indicates that the company appears undervalued based on InvestingPro's Fair Value assessment.

Dividend profile

InvestingPro Tips notes that BCB Bancorp offers a 4% dividend yield and has made dividend payments for 21 consecutive years. The InvestingPro product referenced in the filing is said to provide more than 10 additional proprietary insights for investors following BCBP.


Recent credit and earnings developments

BCB Bancorp disclosed a $15.1 million pre-tax write-down related to a cannabis-related real estate owned property, which will be reflected in its fourth-quarter 2025 financial statements. The company had previously taken a specific reserve against that same property, resulting in a $12.7 million charge-off recorded in the third quarter of 2025.

These adjustments contributed to a net loss of $12.5 million for the quarter and helped drive a full-year 2025 net loss of $14.5 million for the bank.

Analyst and peer activity

Following the disclosures, Piper Sandler raised its price target on BCB Bancorp to $9.00 while keeping a Neutral rating on the shares.

In related regional banking news, Central Bancompany disclosed that the underwriters for its initial public offering fully exercised their option to purchase 2,666,700 additional shares of Class A common stock. That exercise generated roughly $53.2 million in additional net proceeds, lifting total net proceeds from the IPO to approximately $403.7 million.


Bottom line

The director purchase, executed through an IRA, increased Mark Hogan's direct and indirect holdings in BCB Bancorp even as the company reported write-downs tied to a cannabis-related property and posted quarterly and annual losses for 2025. Market commentary accompanying these events includes an InvestingPro Fair Value assessment that labels the stock undervalued and a Piper Sandler price target adjustment to $9.00 with a Neutral stance.

Risks

  • The $15.1 million pre-tax write-down tied to a cannabis-related REO asset and a prior $12.7 million charge-off may continue to pressure reported earnings and capital metrics - impacting the regional banking sector.
  • Prolonged weakness in the stock, which is trading near its 52-week low, could limit liquidity and investor interest in BCBP shares - affecting market participants in small-cap banking stocks.

More from Insider Trading

Itron Finance Executive Sells Shares to Cover RSU Taxes; Analysts Lift Targets After Strong Quarter Mar 2, 2026 First Financial Bancorp internal auditor disposes $9,036 in stock amid strong quarterly results and fresh analyst coverage Mar 2, 2026 Popular Inc. Director Disposes $204K in Shares as Firm Posts Q4 Beat and Lays Out 2026 Growth Plans Mar 2, 2026 Boston Properties Executive Sells $328K in Stock Amid Stock Weakness; Q4 Beat, Analyst Downgrade Add Mixed Signals Mar 2, 2026 FibroBiologics General Counsel Buys $13,056 in Company Stock as Corporate Developments Progress Mar 2, 2026